<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-18T19:44:59Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/392980" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/392980</identifier><datestamp>2025-12-19T20:53:18Z</datestamp><setSpec>com_1810_245118</setSpec><setSpec>com_1810_34581</setSpec><setSpec>col_1810_245119</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Development and characterisation of a novel chimeric antigen receptor against LGR5</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">https://doi.org/10.17863/CAM.123492</dc:identifier>
   <dc:creator>Mueller, Nico</dc:creator>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">0009000883586428</uketdterms:authoridentifier>
   <uketdterms:advisor>de la Roche, Maike</uketdterms:advisor>
   <dcterms:abstract>Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a target gene of the Wnt signalling pathway, is lowly expressed in some stem cell niches and overexpressed in multiple cancers, including pre-B acute lymphoblastic leukaemia (pre-B ALL), hepatocellular carcinoma (HCC) and colorectal cancer (CRC). LGR5 has thus emerged as a promising therapeutic target and has spurred the development of a range of LGR5-targeting immunotherapeutics. In this thesis, I report the generation, characterisation and preclinical validation of novel 2nd generation LGR5scFv-Chimeric Antigen Receptor (CAR) NK and CD8 T cells using flow cytometry, functional in vitro assays and in vivo tumour xenograft models. While LGR5scFv-CAR NK92 cells exhibited high specificity, they had poor efficacy in vitro and failed to survive in vivo. In contrast, LGR5scFv-CAR T cells showed specific and potent killing of LGR5high tumour cells in vitro, and significant anti-tumour activity across pre-B ALL, HCC and CRC tumour xenograft models in vivo. Despite significant reduction in tumour growth, complete eradication was not achieved, likely due to limited CAR T cell persistence. 
Generally, poor persistence remains a major challenge for CAR T cell therapy and often contributes to tumour relapse. While other morphogen pathways such as Notch and Wnt have been shown to have important roles in T cell differentiation and memory development – and our group has uncovered roles for Hh signalling in CD8 T cell cytotoxicity, migration and CD4 T cell polarisation – a role for Hh signalling in T cell memory formation had not been explored. I used knockout mouse models of the Hh ligand Ihh and Hh transcription factor Gli1 in a series of in vitro cytokine polarisation assays, in vivo homeostatic proliferation models and antigen-driven memory formation and rechallenge influenza A virus infection models. Across all systems tested, loss of Ihh or Gli1 in T cells had no effect on memory formation. 
Taken together, I have developed a novel CAR T cell ready for clinical development and found that Hh components Ihh and Gli1 are dispensable for T cell memory formation.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2025-08-02</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>eng</dc:language>
   <uketdterms:sponsor>Cancer Research UK</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/392980</dcterms:isReferencedBy>
   <uketdterms:embargotype>embargo</uketdterms:embargotype>
   <uketdterms:embargodate>2026-12-01</uketdterms:embargodate>
   <dc:identifier xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/bitstreams/63460af8-d9db-4200-ad04-b3c3cb32421e/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">5e7c5910c2e29f2a784519bc7aa725d3</uketdterms:checksum>
   <dcterms:license>https://www.repository.cam.ac.uk/bitstreams/27486f07-59a3-481d-90a0-9b895b2eccd9/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">87eda9de84448d1f82354d60eee3eb5f</uketdterms:checksum>
   <dc:rights>http://purl.org/NET/rdflicense/allrightsreserved</dc:rights>
   <dc:subject>CAR T cell</dc:subject>
   <dc:subject>Immunotherapy</dc:subject>
   <dc:subject>LGR5</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>